A detailed history of Towarzystwo Funduszy Inwestycyjnych Pzu Sa transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Towarzystwo Funduszy Inwestycyjnych Pzu Sa holds 1,189 shares of VRTX stock, worth $516,049. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,189
Previous 1,994 40.37%
Holding current value
$516,049
Previous $888 Million 47.54%
% of portfolio
0.11%
Previous 0.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$366.54 - $479.53 $295,064 - $386,021
-805 Reduced 40.37%
1,189 $466 Million
Q2 2025

Aug 14, 2025

SELL
$421.16 - $509.5 $31,587 - $38,212
-75 Reduced 3.62%
1,994 $888 Million
Q1 2025

Aug 14, 2025

SELL
$402.49 - $513.76 $207,684 - $265,100
-516 Reduced 19.96%
2,069 $1 Billion
Q4 2024

Aug 14, 2025

SELL
$396.64 - $516.74 $5,949 - $7,751
-15 Reduced 0.58%
2,585 $1.04 Billion
Q3 2024

Aug 14, 2025

BUY
$460.0 - $505.78 $32,200 - $35,404
70 Added 2.77%
2,600 $1.21 Billion
Q2 2024

Aug 14, 2025

BUY
$392.81 - $485.53 $3,928 - $4,855
10 Added 0.4%
2,530 $1.19 Billion
Q1 2024

Aug 14, 2025

BUY
$407.69 - $446.08 $238,906 - $261,402
586 Added 29.39%
2,580 $1.08 Billion
Q4 2023

Aug 14, 2025

SELL
$343.0 - $410.68 $15,778 - $18,891
-46 Reduced 1.79%
2,520 $1.03 Billion
Q3 2021

Aug 14, 2025

SELL
$181.39 - $202.99 $13,604 - $15,224
-75 Reduced 2.84%
2,566 $465 Million
Q1 2021

Aug 14, 2025

SELL
$207.02 - $241.31 $144,914 - $168,917
-700 Reduced 20.95%
2,641 $568 Million
Q4 2020

Aug 14, 2025

BUY
$207.01 - $276.09 $691,620 - $922,416
3,341 New
3,341 $790 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Towarzystwo Funduszy Inwestycyjnych Pzu Sa Portfolio

Follow Towarzystwo Funduszy Inwestycyjnych Pzu Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Towarzystwo Funduszy Inwestycyjnych Pzu Sa, based on Form 13F filings with the SEC.

News

Stay updated on Towarzystwo Funduszy Inwestycyjnych Pzu Sa with notifications on news.